News Sentiment

OCUL sentiment intelligence

Ocular Therapeutix Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 10.20 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+5.8% over one week, +14.1% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Citizens reiterates Ocular Therapeutix stock rating on Dextenza sales

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction 5.8% Price confirming higher
Trend fit Trend inactive 14.1% over four weeks
Fair value 25.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 42
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 17
TradingView 7
simplywall.st 5
Investing.com 4
Simply Wall Street 4
GlobeNewswire 3
Stock Titan 3
Finviz 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 19
Analyst action 5
Balance sheet 2
Regulatory and legal 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 63
Stock Traders Daily Direct company coverage

(OCUL) Price Dynamics and Execution-Aware Positioning

This article from Stock Traders Daily provides a detailed AI-driven analysis of Ocular Therapeutix Inc. (NASDAQ: OCUL), highlighting strong near and mid-term sentiment potentially shifting to a weak long-term outlook. It outlines specific institutional trading strategies, includi

Tone
Negative 38/100
Event
Guidance
Published
12 Jul 2026 01:41
Source
Stock Traders Daily
GlobeNewswire Direct company coverage

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix, Inc. announced inducement grants to eleven new non-executive employees, consisting of stock options and restricted stock units. These awards, totaling 34,700 shares for options and 11,375 for RSUs, were made under Ocular’s 2019 Inducement Stock Incentive Plan

Tone
Positive 61/100
Event
Market update
Published
10 Jul 2026 07:11
Source
GlobeNewswire
Simply Wall Street Direct company coverage

Does Ocular Therapeutix (OCUL) Joining Russell Value Indexes Quietly Recast Its Long‑Term Investor Base?

Ocular Therapeutix (OCUL) was recently added to several Russell Value indexes, which could increase its visibility to institutional investors and improve trading volumes. While this inclusion may boost short-term liquidity, the company's long-term investment narrative remains dep

Tone
Neutral 50/100
Event
Balance sheet
Published
10 Jul 2026 05:09
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Ocular Therapeutix (OCUL) Joins Russell Value Indexes, Is The Stock Now Too Pricey?

Ocular Therapeutix (OCUL), recently added to Russell indexes, has seen a sharp rebound in its stock price, but remains down year-to-date. Despite being considered "undervalued" with a fair value of $26 based on the potential of its drug AXPAXLI, its current price-to-sales ratio i

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 12:09
Source
Simply Wall Street
Investing.com Direct company coverage

Ocular Therapeutix options trading jumps to 9,894 contracts

Trading in options for Ocular Therapeutix Inc. (NASDAQ:OCUL) surged to 9,894 contracts by 10:51 a.m. New York time, with call volume notably higher than put volume. Specifically, the July 17, 2026 $9 call option accounted for 9,807 contracts. Despite the increased options activit

Tone
Negative 40/100
Event
Market update
Published
06 Jul 2026 15:11
Source
Investing.com
TradingView Direct company coverage

Ocular Therapeutix Inc Actuals & Estimates (NASDAQ:OCUL)

Ocular Therapeutix Inc. (NASDAQ: OCUL) stock is currently priced at $10.16, showing a 6.94% increase in the past 24 hours. Analysts project a price target range of $18.00 to $34.00, indicating potential growth. The company reported earnings per share of -$0.40 last quarter, missi

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 19:09
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL

This article provides the stock ticker (OCUL) and company name (Ocular Therapeutix, Inc.) along with a financial metric: Price to Earnings Forward. It indicates that the market is currently closed and no trades have occurred for the stock.

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 08:11
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL

This article focuses on the price-to-sales forward metric for Ocular Therapeutix, Inc. (NASDAQ: OCUL). The content, provided by TradingView, lists the company's financial overview and other market data points like financials, news, and technicals. It indicates that the market for

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 15:10
Source
TradingView
Finviz Direct company coverage

OCUL - Ocular Therapeutix Inc Revenue Breakdown

This article provides a comprehensive financial overview of Ocular Therapeutix Inc. (OCUL), detailing its revenue breakdown, market performance, key financial ratios, and analyst recommendations. It includes data on market capitalization, income, sales, earnings per share, inside

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 12:39
Source
Finviz
Pluang Direct company coverage

Ocular Therapeutix to present new retinal disease data at July 2026 scientific and investor conferences

Ocular Therapeutix announced its plans to present new data on its investigational retinal drug AXPAXLI and real-world anti-VEGF treatment outcomes at various scientific and investor conferences in July 2026. These events include the OIS Retina Innovation Summit and the American S

Tone
Positive 66/100
Event
Regulatory and legal
Published
01 Jul 2026 12:11
Source
Pluang
GlobeNewswire Direct company coverage

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced its participation in multiple scientific and investor conferences in July 2026. These events include the 9th Annual OIS Retina Innovation Summit, the American Society of Retina Specialists 44th Annual Meeting, and the HC Wainwrigh

Tone
Positive 70/100
Event
Market update
Published
01 Jul 2026 11:11
Source
GlobeNewswire
Stock Titan Direct company coverage

Ocular Therapeutix will present SOL-1 data at July retina meetings

Ocular Therapeutix (NASDAQ: OCUL) announced its participation in multiple scientific and investor conferences in July 2026. The company will present Phase 3 SOL-1 trial results for OTX-TKI in neovascular age-related macular degeneration (nAMD) at the ASRS 44th Annual Meeting and

Tone
Positive 67/100
Event
Earnings
Published
01 Jul 2026 11:11
Source
Stock Titan
Simply Wall Street Direct company coverage

Does Broad Russell Value Index Inclusion Reshape the Bull Case for Ocular Therapeutix (OCUL)?

Ocular Therapeutix (OCUL) was recently added to several Russell value indices, which could increase its visibility among institutional investors and improve liquidity. While this inclusion may reshape market perception of Ocular Therapeutix's risk profile, the company's investmen

Tone
Positive 66/100
Event
Balance sheet
Published
01 Jul 2026 11:11
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Ocular Therapeutix (OCUL) Could Be 62% Below Fair Value After Axpaxli FDA Feedback

Ocular Therapeutix (OCUL) is in the spotlight due to positive FDA feedback on its drug Axpaxli, intended for wet age-related macular degeneration. Despite a recent share price surge, the company's year-to-date performance is down, though its three-year shareholder return remains

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 03:39
Source
Simply Wall Street
TradingView Direct company coverage

OCUL Forecast — Price Target — Prediction for 2027

This article provides an in-depth forecast for Ocular Therapeutix, Inc. (OCUL) stock, including current price, analyst price targets, and historical performance. It details financial metrics such as EPS, revenue, net income, and EBITDA, along with frequently asked questions about

Tone
Positive 60/100
Event
Earnings
Published
27 Jun 2026 00:09
Source
TradingView
TradingView Direct company coverage

Ocular Therapeutix Inc Actuals & Estimates (BX:0OT)

This article provides an overview of Ocular Therapeutix Inc (BX:0OT) stock, including its current price, market capitalization, and historical performance. It also details financial actuals and estimates, analyst forecasts for future prices, and information on earnings reports, r

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 15:14
Source
TradingView
TradingView Direct company coverage

Ocular Therapeutix Inc Actuals & Estimates (FWB:0OT)

This article provides financial actuals and estimates for Ocular Therapeutix Inc (FWB:0OT), including analyst opinions on future prices, historical stock performance, and past earnings reports. It details the company's revenue, net income, EBITDA, and employee count, confirming t

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 11:09
Source
TradingView
GuruFocus Direct company coverage

OCUL Maintained by Chardan Capital -- Price Target Raised to $23

Chardan Capital has reiterated its "Buy" rating for Ocular Therapeutix (OCUL) and raised its price target from $21.00 to $23.00, signaling optimism about the company's future. Despite this positive analyst sentiment, GuruFocus indicates that OCUL is significantly overvalued by 12

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 14:39
Source
GuruFocus
Insider Monkey Direct company coverage

5 Best Healthcare Stocks to Buy According to Wall Street Analysts

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is highlighted as one of the best healthcare stocks, with H.C. Wainwright increasing its price target to $25 based on positive feedback from a Type C meeting with the FDA for AXPAXLI. The company plans to submit a New Drug Application for A

Tone
Positive 73/100
Event
Analyst action
Published
24 Jun 2026 19:39
Source
Insider Monkey
Moomoo Direct company coverage

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix announced inducement grants under Nasdaq Listing Rule 5635(c)(4). These grants are typically given to new employees as an incentive to join the company. This action reflects the company's efforts to attract and retain talent in line with Nasdaq's regulatory fra

Tone
Neutral 50/100
Event
Regulatory and legal
Published
23 Jun 2026 13:09
Source
Moomoo
Investing.com Nigeria Direct company coverage

H.C. Wainwright raises Ocular Therapeutix price target to $25 on FDA pathway clarity

H.C. Wainwright has increased its price target for Ocular Therapeutix (NASDAQ:OCUL) to $25 from $21, maintaining a Buy rating. This adjustment follows Ocular Therapeutix's Investor Day, where the company provided clarity on its FDA pathway for AXPAXLI, including aligning with the

Tone
Positive 74/100
Event
Analyst action
Published
23 Jun 2026 00:39
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Ocular Therapeutix grants new SVP equity awards tied to hiring

Ocular Therapeutix (NASDAQ: OCUL) has awarded inducement equity grants to Kelley Allison, its new SVP of Market Access and Health Policy, under its 2019 Inducement Stock Incentive Plan. These grants include options for 85,000 shares at an exercise price of $8.99 and 28,000 Restri

Tone
Positive 61/100
Event
Market update
Published
22 Jun 2026 20:11
Source
Stock Titan